Entity

Time filter

Source Type

Beerse, Belgium

Timmerman P.,Janssen R and D NV | White S.,Glaxosmithkline | Cobb Z.,Quotient Bio Analytical science Part of the LGC Group | De Vries R.,Janssen R and D NV | And 2 more authors.
Bioanalysis | Year: 2013

The European Bioanalysis Forum dried blood spots/microsampling consortium is reporting back from the experiments they performed on further documenting the potential hurdles of the DBS technology. Their experiments focused on the impact of hematocrit changes, IS addition, spot homogeneity, aging of spots and stability of fresh blood and cards. Results from these experiments demonstrate that the issues of DBS in regulated bioanalysis are real and that the technology will need additional improvements to be ready for use as a general tool for regulated bioanalysis. In addition, results on fresh blood and card stability were shared at international meetings and will be reported at a later date. © 2013 Future Science Ltd. Source


De Vries R.,Janssen R and D NV | Barfield M.,Glaxosmithkline | Van De Merbel N.,PRA | Schmid B.,Nuvisan GmbH | And 7 more authors.
Bioanalysis | Year: 2013

Background: The European Bioanalysis Forum dried blood spots (DBS)/microsampling consortium is reporting back from the experiments they performed on further documenting the potential hurdles of the DBS technology. This paper is focused on the impact of hematocrit changes on DBS analyses. Results: The hematocrit can have an effect on the size of the blood spot, on spot homogeneity and on extraction recovery in a compound-dependent manner. The extraction recovery can change upon aging in an hematocrit-dependent way. Different card materials can give different outcomes. Conclusions: The results from the conducted experiments show that the issues of DBS in regulated bioanalysis are real and that the technology will need improvements to be ready for use as a general tool for regulated bioanalysis. © 2013 Future Science Ltd. Source

Discover hidden collaborations